International Patient Begins First-Ever CAR-T Therapy for Solid Tumors

Groundbreaking CAR-T Therapy for Solid Tumors at Jiahui International Cancer Center

In a historic milestone for cancer treatment, the Jiahui International Cancer Center (JICC) in Shanghai has welcomed the world’s first international patient to undergo CAR-T therapy specifically designed for solid tumors. This groundbreaking treatment, known as Satri-cel, is the first of its kind to receive global approval for this application and reflects a significant leap in the advancement of oncological therapies developed in China.

The patient, a 59-year-old male from New Zealand named Josh, was diagnosed with advanced gastroduodenal cancer, which left him with limited conventional treatment options in his home country. After conducting biomarker tests, which confirmed his suitability for the CAR-T therapy (positive for Claudin 18.2 and negative for HER2), he traveled to Shanghai to participate in this pioneering clinical procedure.

Upon his arrival, a multidisciplinary team at the JICC conducted a comprehensive treatment evaluation and planning session. Following these assessments, Josh successfully completed the leukoapheresis procedure, a crucial step where his T-cells were harvested for further processing. The manufacturing of his CAR-T cells is currently underway, and the reinfusion of these modified cells is scheduled for the coming weeks.

The approval of Satri-cel came just days before Josh's treatment initiation, emphasizing the urgency and excitement surrounding this innovative therapy. Dr. Linli Xuan, the Head of Medical Oncology at JICC, remarked, "The approval of Satri-cel represents a historic achievement not only for patients with advanced gastric cancer but also for the future of global oncology. We feel honored that Josh chose JICC for this pioneering treatment. As innovative therapies developed in China continue to gain international recognition, we are witnessing a growing interest from patients around the world seeking access to these advances. Our commitment is to combine cutting-edge therapies with comprehensive multidisciplinary care and specialized support for international patients."

The Jiahui International Cancer Center is at the forefront of cancer care, offering integrated oncology services that include medical oncology, surgical oncology, radiotherapy, precision medicine, and advanced cellular therapies. By adopting a multidisciplinary care model and utilizing its International Patient Office, JICC supports global patients by reviewing medical records, coordinating multilingual consultations, planning treatments, and providing logistical assistance along with continuous follow-up care.

As the landscape of cancer treatment evolves, the groundbreaking achievement at JICC reaffirms the center’s commitment to leading the charge in international cancer therapy innovation and access. It also underscores the importance of global collaboration in the fight against cancer and brings hope to patients worldwide who seek advanced treatment options that were once unavailable. The international healthcare community eagerly watches JICC as it paves the way for further innovations in cancer care.

For more detailed insights on this exciting development, readers can visit Jiahui International Cancer Center's official site: Jiahui International Cancer Center.

As we continue to monitor the advancements in CAR-T therapies and their impacts on oncology, this step represents not just a personal victory for a single patient but also an opening door for many seeking cutting-edge treatment options worldwide.